Jolimoy, Patrick Roignot, Charles Coutant, Isabelle
Desmoulins, Marc Maynadie, Tienhan Sandrine Dabakuyo-Yonli
The Breast: Published:
June 11, 2021
Purpose
To identify prognostic factors of invasive–disease free
survival (iDFS) in women with non-metastatic hormone receptor positive (HR+)
breast cancer (BC) in daily routine practice.
Methods
We performed a retrospective study using data from the Côte
d’Or breast and gynecological cancer registry in France. All women diagnosed
with primary invasive non-metastatic HR + BC from 1998 to 2015 and
treated by endocrine therapy (ET) were included. Women with bilateral tumors or
who received ET for either metastasis or relapse were excluded. We performed
adjusted survival analysis and Cox regression to identify prognostic factors of
iDFS.
Results
A total of 3976 women were included. Age at diagnosis, ET
class, SBR grade, treatment, stage and comorbidity were independently
associated with iDFS. Women who had neither surgery nor radiotherapy had the
highest risk of recurrence (HR = 3.75, 95%CI [2.65–5.32], p < 0.0001).
Receiving aromatase inhibitors (AI) was associated with a lower risk of
recurrence (HR = 0.80, 95%CI [0.54–0.90], p = 0.055) compared to tamoxifen.
Compared to women with no comorbidities, women with 1 or 2 comorbidities were
more likely to receive AI (OR = 1.63, 95%CI [1.22–2.17], p = 0.0009).
Conclusions
Comorbidities, age at diagnosis and previous treatment were
associated with iDFS in non-metastatic HR + BC patients. This study
also showed that women who received tamoxifen for their cancer experienced
worse iDFS compared to women treated with AI.
